Abstracts tagged "Bioinformatics"

Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Sagrario Corrales¹, Carlos Perez-Sanchez¹, Laura Muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera³, María Lourdes Ladehesa-Pineda⁵, Pilar Font¹, Ismael Sánchez Pareja¹, María Carmen Ábalos-Aguilera⁶, Desiree Ruiz-Vilchez⁴, Christian Merlo⁷, Mª Angeles Aguirre-Zamorano⁸, Tomás Cerdó¹, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁵, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Hospital Reina Sofía, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…
Abstract Number: 1422 • ACR Convergence 2024
Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery
Konstantinos Panagiotopoulos¹, Nikos Tsiknakis², Dimitrios Zaridis³, Athanasios Tzioufas⁴, Dimitrios I. Fotiadis⁵ and Andreas Goules⁶, ¹Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, ²Karolinska Institutet, Department of Oncology-Pathology, Computational BioMedicine Laboratory, Foundation for Research and Technology Hellas, Stockholm, Sweden, ³School of Electrical & Computer Engineering and Biomedical Research Institute National Technical University of Athens and FORTH, Unit of Medical Technology and Intelligent Information Systems, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Ioannina, Greece, ⁴LAIKO HOSPITAL, Athens, Greece, ⁵Unit of Medical Technology and Intelligent Information Systems, University of Ioannina & FORTH, Ioannina, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece
Background/Purpose: Sjogren's Disease (SjD) is characterized by focal sieladenitis in minor salivary gland biopsies (mSGB), which is evaluated using the Focus Score (FS). FS ≥…
Abstract Number: 2160 • ACR Convergence 2024
Development of a Lupus Chatbot
Leila Khalili¹, Pooja Desai², Maya Souvignier¹, Sophie Askanase², Lena Mamykina² and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²CUIMC, New York, NY
Background/Purpose: Artificial Intelligence (AI) is poised to take the world of medicine by storm. The next decade will likely bring major changes in technology use…
Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Ana Merino Vico¹, Yosta Vegting¹, Aldo Jongejan¹, Jan Piet van Hamburg¹, Perry moerland¹, Sander Tas² and Marc Hilhorst¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
Abstract Number: 0618 • ACR Convergence 2024
Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls
Liyoung Kim¹, Vitor Aguiar², Daniela Fernandez-Salinas³, Jeffrey Sparks⁴, Peter Nigrovic¹, Joyce Chang² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Polygenic risk scores quantify the composite impact of numerous genetic variants to predict disease risk. However, conventional polygenic risk scores have limitations in revealing…
Abstract Number: 1657 • ACR Convergence 2024
Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis
Marie Binvignat¹, Maria Marco-Salvador¹, Johanna Dubois¹, Paul Stys¹, Alice Courties², Fabien Pitoiset¹, Alexandra Roux³, Michele Barbier⁴, Roberta Lorenzon², Signe Hassler³, Claire Ribet¹, helene Vantomme¹, Leslie Adda¹, Vanessa Mhanna¹, Nicolas Coatnoan², Gwladys Fourcade¹, Vimala Didelot¹, PIerre Barennes¹, Lise Minssen², Caroline Aheng¹, Sanchita Bhattacharya⁵, Yannick Marie⁶, Atul J. butte⁵, Adrien Six¹, Nicolas Tchitcheck¹, Michelle Rosenzwajg¹, Francis Berenbaum¹, David Klatzmann¹, Encarnita Mariotti-Ferrandiz¹ and Jérémie Sellam⁷, ¹Sorbonne University, Paris, France, ²AP-HP, Paris, France, ³Sorbonne University, Paris, ⁴AP-HP, Paris, ⁵UCSF, San Francisco, ⁶ICM, Paris, France, ⁷Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Pain is the main osteoarthritis (OA) symptom and remains poorly understood. While significant attention has been given to the potential role of innate immunity,…
Abstract Number: 2244 • ACR Convergence 2024
Unveiling Synovial Protein Contributions to Serum Inflammation, Disease Activity, and Treatment Outcomes in RA Patients
Chary Lopez-Pedrera¹, Sagrario Corrales², Julio Osuna³, Rafaela Ortega-Castro⁴, Jerusalén Calvo³, María Lourdes Ladehesa-Pineda¹, Ismael Sánchez Pareja², Laura Muñoz-Barrera², Desiree Ruiz-Vilchez³, Christian Merlo⁵, Mª Angeles Aguirre-Zamorano⁶, Nuria Barbarroja², Tomás Cerdó², Rosa ortega³, Marta Alarcon-Riquelme⁷, Carlos Perez-Sanchez², Alejandro Escudero-Contreras² and Concepción Aranda-Valera⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁵Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁷Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain
Background/Purpose: Characterize synovial tissue-secreted proteins in RA patients that contibute to serum inflammatory profiles based on immune cell infiltration.Identify RA patient subsets with distinctive serum…
Abstract Number: 0026 • ACR Convergence 2024
Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin
Michael Newton¹, Aanya Mohan², Tareq Hanna³, Dana Orange⁴, John Varga² and Tristan Maerz², ¹University of Michigan, South Lyon, MI, ²University of Michigan, Ann Arbor, MI, ³Wayne State University, Detroit, MI, ⁴The Rockefeller University, New York, NY
Background/Purpose: Synovial fibrosis is a hallmark of osteoarthritis (OA) and a clinical correlate to joint pain. Fibrosis of skin, lungs and other organs is the…
Abstract Number: 0621 • ACR Convergence 2024
Predictive Parameters of Disease-related Damage Accrual in Patients with Systemic Lupus Erythematosus: A Machine Learning Analysis
Omer Pamuk¹ and Hasan Cetin², ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Cleveland Clinic Cole Eye Institute, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory disease that can affect multiple organs and systems. While there has been an improvement in…
Abstract Number: 1692 • ACR Convergence 2024
Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Trinitee Oliver¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin⁶ and Richard Ainsworth⁶, ¹Cedars-Sinai Medical Center, Hawthorne, CA, ²University of California, San Francisco, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
Abstract Number: 2256 • ACR Convergence 2024
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
Jia Yi Hee¹, Hendrik Nel², Yann Abraham³, Katrina Chakradeo⁴, Michelle Roch⁴, Tom Lynch⁵, Lyn March⁵, Mihir Wechalekar⁶, Helen Keen⁷ and Ranjeny Thomas⁸, ¹The University of Queensland, Woolloongabba, Queensland, Australia, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Janssen Research and Development, Beerse, Belgium, ⁴The University of Queensland, Brisbane, Australia, ⁵The University of Sydney, Sydney, New South Wales, Australia, ⁶Flinders Medical Centre, Adelaide, Australia, ⁷Fiona Stanley Hospital, Murdoch, Western Australia, Australia, ⁸University of Queensland, Brisbane, Australia
Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
Abstract Number: 0044 • ACR Convergence 2024
Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes
Cankut Cubuk¹, Rachel Lau¹, Vinothini Rajeeve², Pedro Cutillas², Rebecca Hands¹, Liliane Fossati-Jimack¹, Anna Surace¹, Alessandra Nerviani¹, Felice Rivellese¹, Myles Lewis³ and Costantino Pitzalis⁴, and the R4RA Collaborative Group, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ²Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴QMUL, Bromley Kent, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an incurable autoimmune disease where response to therapy is heterogenous. Clinically indistinguishable RA patients can be classified histo-pathologically into three…
Abstract Number: 0783 • ACR Convergence 2024
Spatial Reconstruction of Interstitial Lung Disease
Miles Tran¹, Ce Gao¹, Mukta G Palshikar¹, Jessica Liu¹, Mari Kamiya¹, Gregory McDermott², Elena Joerns³, Daimon Simmons¹, Rachel Gate⁴, Deepak Rao⁵, Jeffrey Sparks⁶, Edy Kim⁷, Kevin Wei⁸ and ilya Korsunsky¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Mayo Clinic, Rochester, MN, ⁴10x Genomics, Pleasanton, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Interstitial lung disease encompasses a heterogenous group of conditions broadly characterized by inflammation and progressive fibrosis of the lung[1]. There remains an ongoing search…
Abstract Number: 1711 • ACR Convergence 2024
Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Sreemoyee Ghosh¹, Chiara Pastrello², Omar F. Cruz-Correa³, Darshini Ganatra⁴, Katerina Oikonomopoulou³, Melanie Anderson⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Institute of Medical Science, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis (Pso) is a chronic immune mediated inflammatory skin disease. Up to 24% of Pso patients develop psoriatic arthritis (PsA). Pathophysiology of PsA is…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…

« Previous Page
1
…
4
5
6
7
8
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].